Explore 3 Stock Ideas & Industry Insights Download Free Report

888-969-2592
Shopping Cart 0
countryflagCA
Login

OraSure Technologies Inc

Healthcare US OSUR

4.24USD
0.08(1.92%)

Last update at 2026-06-23T20:00:00Z

Day Range

4.114.29
LowHigh

52 Week Range

4.388.45
LowHigh

Fundamentals

  • Previous Close 4.16
  • Market Cap357.22M
  • Volume562803
  • P/E Ratio16.10
  • Dividend Yield-%
  • EBITDA35.26M
  • Revenue TTM304.64M
  • Revenue Per Share TTM4.14
  • Gross Profit TTM 147.64M
  • Diluted EPS TTM0.30

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Analyst Recommendations

Financials

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Type yearly yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Income before tax -16.47700M -9.29200M -3.52400M 21.33M 31.72M
Minority interest - - - - -
Net income -17.93500M -22.99800M -14.92200M 16.66M 20.40M
Selling general administrative 68.21M 50.33M 42.65M 35.29M 38.33M
Selling and marketing expenses 49.24M 44.75M 34.46M 31.87M 30.61M
Gross profit 147.64M 117.60M 101.87M 94.58M 113.61M
Reconciled depreciation 15.54M 12.49M 9.71M 7.73M 7.22M
Ebit -4.66700M -11.64900M -6.27600M -3.01500M 28.43M
Ebitda 10.87M -13.13400M -7.37500M 4.71M 35.65M
Depreciation and amortization 15.54M -1.48500M -1.09900M 7.73M 7.22M
Non operating income net other 6.48M 0.87M 1.65M - 3.29M
Operating income -4.66700M -11.64900M -6.27600M -3.01500M 28.43M
Other operating expenses 393.52M 245.32M 178.00M 146.81M 153.31M
Interest expense 10.43M 16.34M 13.56M 24.35M 3.29M
Tax provision 1.46M 13.71M 11.40M 4.67M 11.32M
Interest income - - - 1.34M 0.83M
Net interest income - - - - -
Extraordinary items - - - - 17.72M
Non recurring 17.10M - - - -
Other items - - - - -
Income tax expense 1.46M 13.71M 11.40M 4.67M 11.32M
Total revenue 387.48M 233.67M 171.72M 154.60M 181.74M
Total operating expenses 153.68M 129.25M 108.14M 86.78M 85.18M
Cost of revenue 239.84M 116.07M 69.85M 60.02M 68.13M
Total other income expense net -11.81000M 2.36M 2.75M 24.35M 3.29M
Discontinued operations - - - - -
Net income from continuing ops -17.93500M -22.99800M -14.92200M 16.66M 20.40M
Net income applicable to common shares -17.93400M -22.99800M -14.92200M 16.66M 20.40M
Preferred stock and other adjustments - - - - -
Breakdown 2023-12-31 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Type yearly yearly yearly yearly yearly
Date 2023-12-31 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Total assets 482.85M 444.71M 460.99M 454.47M 349.30M
Intangible assets 1.21M 11.69M 14.34M 17.90M 14.67M
Earning assets - - - - -
Other current assets 8.27M 47.84M 17.30M 8.79M 8.11M
Total liab 52.17M 81.08M 80.46M 55.90M 42.15M
Total stockholder equity 430.67M 363.62M 380.53M 398.57M 307.14M
Deferred long term liab - 0.41M 2.23M 1.20M -
Other current liab 22.71M 25.83M 33.98M 22.63M 17.79M
Common stock - - 380.53M - 307.14M
Capital stock 0.00000M 0.00000M 0.00000M 0.00000M 0.00000M
Retained earnings -83.93100M -138.38700M -120.45300M -97.45500M -82.53300M
Other liab - 1.09M 12.39M 4.93M 3.86M
Good will 35.70M 35.10M 40.28M 40.35M 36.20M
Other assets - 0.06M 0.05M 7.75M 3.16M
Cash 290.41M 83.98M 116.76M 160.80M 75.72M
Cash and equivalents - - - - -
Total current liabilities 39.54M 70.39M 68.06M 46.49M 32.71M
Current deferred revenue 1.56M 2.27M 2.94M 4.81M 3.71M
Net debt -276.90300M -71.43300M -104.48800M -154.67400M -70.13700M
Short term debt 2.12M 2.94M 3.12M 1.64M 1.65M
Short long term debt - - - - -
Short long term debt total 13.50M 12.55M 12.27M 6.13M 5.58M
Other stockholder equity 529.54M 520.45M 511.06M 505.12M 401.81M
Property plant equipment - 59.41M 88.16M 51.86M 37.29M
Total current assets 386.46M 325.72M 288.43M 288.89M 224.55M
Long term investments - 0.00000M 17.01M 47.72M 33.42M
Net tangible assets - 316.83M 325.91M 340.32M 256.27M
Short term investments 0.00000M 26.87M 36.28M 48.60M 80.62M
Net receivables 40.17M 70.80M 64.95M 38.84M 36.95M
Long term debt - - - - -
Inventory 47.61M 96.23M 53.14M 31.86M 23.16M
Accounts payable 13.15M 39.35M 28.02M 17.41M 9.57M
Total permanent equity - - - - -
Noncontrolling interest in consolidated entity - - - - -
Temporary equity redeemable noncontrolling interests - - - - -
Accumulated other comprehensive income -14.94100M -18.43500M -10.07700M -9.09700M -12.13600M
Additional paid in capital - - - - -
Common stock total equity - - - - -
Preferred stock total equity - - - - -
Retained earnings total equity - -138.38700M -120.45300M -97.45500M -
Treasury stock - - - - -
Accumulated amortization - - - - -
Non currrent assets other 0.01M 12.37M 10.53M 6.55M 2.27M
Deferred long term asset charges - - - - -
Non current assets total 96.39M 118.99M 172.56M 165.58M 124.75M
Capital lease obligations 13.50M 12.55M 12.27M 6.13M 7.22M
Long term debt total - - - - 1.37M
Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Type yearly yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Investments 24.54M 42.10M 17.58M -19.79700M -11.08300M
Change to liabilities 5.33M 6.52M 14.68M -1.83400M -7.09800M
Total cashflows from investing activities 21.09M -5.50100M -14.02900M -19.79700M -17.42700M
Net borrowings -1.38100M -0.68600M -0.68700M -1.16600M -1.16600M
Total cash from financing activities -3.82800M -2.81700M 92.48M -4.68200M -1.89100M
Change to operating activities -5.72100M -5.38600M 7.19M -3.81700M -7.67200M
Net income -17.93400M -22.99800M -14.92200M 16.66M 20.40M
Change in cash -32.78200M -44.04000M 85.09M -12.72300M 15.57M
Begin period cash flow 116.76M 160.80M 75.72M 88.44M 72.87M
End period cash flow 83.98M 116.76M 160.80M 75.72M 88.44M
Total cash from operating activities -47.20200M -35.38200M 5.81M 9.80M 39.09M
Issuance of capital stock 0.00000M 0.00000M 95.04M - -
Depreciation 15.54M 12.49M 9.71M 7.73M 7.22M
Other cashflows from investing activities 3.32M -10.98200M -4.93600M 0.35M -11.08300M
Dividends paid - - -3.22200M - -
Change to inventory -43.04800M -27.94100M -8.60700M -1.32400M -3.85700M
Change to account receivables -25.16200M -6.45100M -2.32400M -2.21000M 6.63M
Sale purchase of stock -2.25400M -2.11300M -2.08800M -3.71200M -3.59200M
Other cashflows from financing activities -0.20800M -0.01800M 3.44M 0.20M 1.70M
Change to netincome 25.67M 13.62M 6.97M -5.00600M 13.92M
Capital expenditures 63.91M 48.12M 28.92M 9.31M 6.34M
Change receivables -25.16200M -6.45100M -2.32400M - 6.63M
Cash flows other operating -7.36500M -9.78800M 0.62M - 2.65M
Exchange rate changes - - - - -
Cash and cash equivalents changes -29.94500M -43.70000M 84.26M - 19.77M
Change in working capital -70.56400M -38.43500M 4.69M -9.18500M -2.44600M
Stock based compensation 11.62M 7.81M 7.14M 4.06M 15.24M
Other non cash items 15.79M 4.72M -0.42400M -7.99700M -0.40000M
Free cash flow -111.11100M -83.49900M -23.11700M 0.49M 32.75M

Peer Comparison

Sector: Healthcare Industry: Medical Instruments & Supplies

Company Change (USD) Price (USD) Trailing PE (x) Forward PE (x) Price Sales TTM (x) Price to Book Value (x) Enterprise Value to Revenue (x) Enterprise Value to EBITDA (x)
OSUR
OraSure Technologies Inc		 0.08 1.92% 4.24 16.10 - 1.04 0.98 0.36 2.26
ISRG
Intuitive Surgical Inc		 0.23 0.06% 403.18 73.05 61.73 19.15 10.25 18.41 59.92
ESLOF
EssilorLuxottica Société anonyme		 - -% 192.00 44.84 27.62 4.07 2.49 3.71 16.04
ESLOY
Essilor International SA		 -0.49 0.51% 95.87 41.68 27.25 3.94 2.45 3.71 16.04
BDX
Becton Dickinson and Company		 3.21 2.28% 143.92 25.56 12.48 2.59 1.76 2.89 12.55

Reports Covered

Stock Research & News

View All

Profile

OraSure Technologies, Inc., together with its subsidiaries, provides point-of-care and home diagnostic tests, specimen collection devices, and microbiome laboratory and analytical services in the United States, Europe, and internationally. The company's products include InteliSwab COVID-19 rapid test, InteliSwab COVID-19 rapid test pro, InteliSwab COVID-19 rapid test rx, OraQuick Rapid HIV test, OraQuick In-Home HIV test, OraQuick HIV self-test, OraQuick HCV rapid antibody test, OraQuick Ebola rapid antigen test, OraSure oral fluid collection device used in conjunction with screening and confirmatory tests for HIV-1 antibodies; Intercept drug testing systems; immunoassay tests and reagents; and Q.E.D. saliva alcohol test. It also offers genomic products under the Oragene and ORAcollect brands for collecting genetic material from human saliva; Colli-Pee collection devices for the volumetric collection of void urine samples; and microbiome laboratory testing and analytical services. In addition, the company provides microbiome products, such as OMNIgene GUT for self-collecting microbial DNA from feces or stool samples for gut microbiome profiling; OMNIgene GUT DNA and RNA collection devices; and OMNIgene GUT Dx collection device for collection of human fecal samples and the stabilization of DNA from the bacterial community. Additionally, it provides other diagnostic products, such as immunoassays and other in vitro diagnostic tests. The company markets its products to clinical laboratories, hospitals, clinics, community-based organizations and other public health organizations, distributors, government agencies, physicians' offices, commercial and industrial entities, disease risk management, diagnostics, pharmaceutical, biotech, nutrition, companion animal, and environmental markets. OraSure Technologies, Inc. was incorporated in 2000 and is based in Bethlehem, Pennsylvania.

OraSure Technologies Inc

220 East First Street, Bethlehem, PA, United States, 18015

Key Executives

Name Title Year Born
Mr. Scott Gleason Sr. VP of Investor Relations & Corp. Communications 1979
Ms. Kathleen Gallagher Weber Chief Product Officer 1967
Ms. Carrie Eglinton Manner Pres, CEO & Director 1975
Mr. Kenneth J. McGrath Chief Financial Officer NA
Ms. Michele Marie Miller Sr. VP, Chief Accounting Officer, Controller & Assistant Sec. 1974
Mr. Stefano Taucer Gen. Counsel & Corp. Sec. NA
Mr. David A. Rappaport C.F.A., CFA Sr. VP Corp. Devel., Strategy & Integration NA
Amy Steigerwalt Sr. VP of HR NA
Mr. Zachary Wert Sr. VP of Global Operations NA
Ms. Trace Custer Sr. VP of Quality & Regulatory NA

Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.